Creatinine Measurement Market - Forecasts from 2024 to 2029

The creatinine measurement market was valued at US$294.49 million in 2022 and is expected to grow at a CAGR of 9.38% during the forecast period.

The creatinine measurement is performed to check the function of the kidney in the human body. The leftover chemical compound found in the human body is called creatinine. The status of the kidney can be figured out by measuring creatinine levels in the human body. The creatinine levels can be measured from blood samples and urine samples. After the process, the filtered-out creatinine exits the human body with urine as filtered waste.

Driving factors for the creatinine measurement market

The major factor influencing the growth of the creatinine measurement market is the growing prevalence of renal disorders and other chronic illnesses that affect renal function. Implementation of suitable government initiatives and increasing adoption of preventive healthcare are other initiatives that fuel the creatinine measurement market. Moreover, the increase in the geriatric population and various product developments are some other factors that further propel the creatinine measurement market.

Growing prevalence of kidney-related disease

The worldwide creatinine measurement market is anticipated to rise over the next years as a result of rising rates of diabetes and chronic kidney disease (CKD), an aging population, and increased R&D efforts. The global creatinine measurement industry is also being driven by the development of exogenous marker components, a rise in government financing, and an increase in clinical laboratory operations. Serum creatinine tests are carried out by clinical chemistry labs all over the world. Favourable reimbursement policies and cutting-edge designs created by market vendors, including occlusive cuffs or pumps with implant connections, are also anticipated to fuel this creatinine measurement market growth.

Increasing use of point-of-care creatinine instruments

Point-of-care creatinine instruments are used for early diagnosis of chronic kidney diseases throughout the screening programs. The use of portable devices for creatinine point-of-care analysis enables fast diagnostic results in homecare settings. This also proves to be beneficial for end-stage renal failure cases which require renal replacement. The use of home creatinine testing with POC leads to more renal function analysis owing to simplicity and convenience.

Technological advancement in the detection of creatinine

A straightforward, transportable, and sensitive biosensor is constructed using single-mode fiber-multicore fiber-multimode fiber-single mode fiber (SMFMCF-MMF-SMF) to detect creatinine in the human body. Chemical etching was used to shrink the sensing probe's diameter to 90 m (EWs), which allowed for the generation of powerful evanescent waves. The sensor probe is functionalized using graphene oxide (GO), gold nanoparticles (AuNPs), molybdenum disulfide nanoparticles (MoS2-NPs), and the enzyme creatininase (CA). Creatinine concentration is measured using fiber optic localized surface plasmon resonance (LSPR). To boost biocompatibility, two-dimensional (2D) materials (GO and MoS2-NPs) are used. CA is also used to increase probe specificity, while EWs are used to improve the LSPR effect of AuNPs.

Rising demand for creatinine measurement kits and reagents

A growth in the prevalence of various chronic diseases that affect renal function also adds to the need for creatinine measurement kits and reagents. For instance, the majority of all occurrences of renal failure are caused, respectively, by diabetes and high blood pressure. An increase in the elderly population worldwide, who are more susceptible to renal problems, favourable government laws designed to promote renal health, and the development of monitoring technology all contribute to the creatinine measurement market growth. Employing point-of-care creatinine measurement equipment as a quick way is one of these potential technical developments.

Growing adoption for enzymatic method

The enzymatic approach converts creatinine to phosphocreatine using the enzyme creatinine phosphokinase (CPK). The measurement of phosphocreatine is then utilized to determine the creatinine concentration. The enzymatic approach may be used in serum, plasma, or whole blood and is quicker than Jaffe's kinetic method. A linear dynamic range of around 30 mg/dL to 700 mg/dL is also seen. The primary drawbacks of the enzymatic approach are its susceptibility to interference with excessive bilirubin, ascorbic acid, and chromogen concentrations in urine samples.

Serum creatinine is anticipated to hold the maximum market share

One of the most used laboratory tests for renal function is serum creatinine. As a measure of kidney function, it is used to calculate the estimated glomerular filtration rate (eGFR). It serves as an excellent indication for identifying chronic renal disorders. The ideal indicator of kidney function, the glomerular filtration rate (GFR), is negatively correlated with the blood creatinine content. GFR is often approximated using equations that take into account endogenous filtration indicators such as serum creatinine (sCr) due to the time-consuming nature of monitoring GFR.

Growing launches and advancements in serum creatinine tests, expanding R&D activity, prominent companies adopting important strategic initiatives, and rising prevalence of chronic renal disease are all driving creatinine measurement market growth.

In North America, it is projected that the preimplantation genetic testing market will grow steadily.

The creatinine measurement market is anticipated to grow during the projected period due to several reasons, including the rising incidence of renal illnesses, the presence of a well-developed healthcare infrastructure, the rising awareness of preventive healthcare, and the acceptance of testing in the area. For instance, the National Institute of Diabetes and Digestive and Kidney Diseases estimates that 37 million individuals in the United States, or almost one-seventh of the population, are affected by chronic kidney disease (CKD). Americans who have diabetes or high blood pressure, the two most common causes of renal disease, are considerably more likely to develop CKD.

Market Key Developments

• In July 2022, Creative Enzymes, one of the top manufacturers of diagnostic enzymes, introduced new enzymes for the manufacture of creatinine test kits.
• In March 2022, The Nova Max Pro Creatinine/eGFR Metre System is now available in all countries that are members of the European Economic Area. Nova Max Pro is a significant new tool for improving renal care through early kidney disease identification and kidney function assessment outside of the hospital.

Segmentation:

By Type

• Jaffe’s Kinetic Method
• Enzymatic Method

By Sample Type

• Blood/Serum
• Urine

By End-User

• Hospitals
• Diagnostic Laboratories

By Geography

• North America
• United States
• Canada
• Mexico
• South America
• Brazil
• Argentina
• Others
• Europe
• United Kingdom
• Germany
• France
• Spain
• Others
• Middle East and Africa
• Saudi Arabia
• UAE
• Israel
• Others
• Asia Pacific
• Japan
• China
• India
• South Korea
• Indonesia
• Thailand
• Others